Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00255359
Other study ID # 200517-HMO-CTIL
Secondary ID
Status Withdrawn
Phase Phase 1
First received November 16, 2005
Last updated November 5, 2007
Start date February 2006
Est. completion date November 2007

Study information

Verified date November 2007
Source Hadassah Medical Organization
Contact n/a
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

The study will be a randomized, double blind, placebo controlled, dose rising study in Interferon alpha (IFN-alpha) non-responder HCV infected patients or HCV patients who have relapsed following IFN-alpha therapy. Eligible subjects must have compensated liver disease and serum HCV RNA concentrations above 100,000 IU/mL at screening. The study will include both a single dose period for the evaluation of acute toxicity and single dose pharmacokinetics and a consecutive multi-dose period for the determination of longer-term safety, multiple-dose pharmacokinetics and antiviral activity. The objectives of this study are to evaluate the safety, tolerability, and antiviral activity of escalating single and multiple doses of XTL 2125 in patients with chronic hepatitis C virus infection and to assess the single- and multiple-dose pharmacokinetics of XTL 2125


Description:

The study will be of a randomized, double blind, placebo controlled, multicenter design with sequential ascending doses of XTL 2125 in HCV-infected patients with compensated liver disease who did not respond to IFN-alpha therapy or relapsed following this therapy.

This study will include both a single dose session and a multiple dose session. In the single dose session, patients will be randomized to receive a single oral dose of either XTL 2125 or placebo on Day 1, in a dose-escalating design, followed by a multiple dose session that will start on day 8 and will continue for 14 days. The same patients will receive XTL 2125 three times daily at the same dose administered in the single dose session.

The following doses will be administered to groups of 8 patients each: 10 mg, 25 mg, 50 mg, 150 mg, 300 mg and 450 mg. Within each group, 6 subjects will receive XTL 2125 and 2 subjects will receive placebo. No patient will be enrolled in more than one dose level. Doses should be administered one hour before meals with 240 cc water.

Additional patients may be enrolled at previous or intermediate doses to obtain additional safety or pharmacokinetic/pharmacodynamic data and to more accurately define the Maximum Tolerated Dose (MTD).

The MTD will be defined as the last dose level that is successfully administered with a decision to escalate to the next level. If the decision not to escalate to the next level is made then a cohort that receives XTL 2125 at a dose half-way between the last tolerated dose and the non-tolerated dose may be enrolled at the discretion of the Sponsor. If this dose is successfully administered without violating the dose escalation rules, then this interim dose will be considered the MTD.

Six dose cohorts will be prospectively indicated, although additional cohorts may be scheduled at intermediate doses if warranted by the data.


Recruitment information / eligibility

Status Withdrawn
Enrollment 60
Est. completion date November 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.

- Adults 18 to 70 years of age.

- Documented history of positive HCV serology.

- Compensated liver disease as defined by the following at screening: PT greater or equal to 60%, INR < 1.5, serum albumin greater or equal 3.4 g%, and serum bilirubin < 2 mg% (unless dx of Gilbert's Syndrome).

- Serum HCV RNA greater or equal 100,000 IU/mL at screening.

- Patients who were treated and did not respond to IFN-alpha therapy or who withdrew from this therapy within 30 days prior to screening.

- Patients who had completed a fully prescribed course of an approved IFN alpha -based treatment and relapsed following the end of the treatment.

- Patients must be sterile or infertile or use an approved method of contraception from the time that the first dose of study medication is taken until three months following study completion or discontinuation.

- Screening labs as follows: platelet count greater or equal 120,000/mm3; ANC greater or equal 1000/mm3; hemoglobin greater or equal 11.0 g/dL for females and greater or equal 12.0 g/dL for males; serum ALT within normal limits or < 5 x ULN.

- Alpha fetoprotein <25 microg/L at screening.

Exclusion Criteria:

- Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease other than hepatitis C or any other disease which in the judgment of the investigator would interfere with the study or confound the results.

- Patients with positive HIV serology or positive HBsAg at screening.

- Patients who were not treated previously with the current approved therapy against HCV.

- Patients who have received any previous treatment for HCV infection other than an approved regimen of IFN alpha and ribavirin within 30 days prior to screening.

- Patients with decompensated liver disease or evidence of advanced liver disease such as the presence of ascites, bleeding varices or hepatic encephalopathy.

- Female patients who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.

- History of alcohol or drug abuse within 6 months of screening.

- Patients who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.

- Patients with poor venous access

- History or evidence of hepatocellular carcinoma (HCC).

- Use of prescription or non-prescription drugs that are known to be metabolized in the liver and can potentially interfere with the study medication (such as Marcolide antibiotics, azole antifungals, warfarin, carbamazepine, cyclosporine, midazolam, phenytoin, valporic acid, chlorpromazine, rifampin, quinidine, diazepam and digoxin) 90 days prior to screening.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
XTL-2125


Locations

Country Name City State
Israel Hadassah Medical Organization Jerusalem

Sponsors (2)

Lead Sponsor Collaborator
Hadassah Medical Organization XTL Biopharmaceuticals

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety:
Primary • adverse events, serious adverse events
Primary • laboratory abnormalities by highest toxicity grade
Primary • laboratory abnormalities by largest increase in toxicity grade from baseline
Primary Efficacy:
Primary • Median change from baseline in serum HCV RNA (log10 IU/mL) at day 22.
Primary • Median maximum change from baseline at any time between Day 8 and Day 22.
Primary • Median change from baseline in serum ALT at day 22.
Primary • Percent of patients within each cohort with serum HCV RNA declining at least a 1 log10 from baseline at any assessment between Day 8 and 22.
Primary • AUC using the trapezoidal rule, minus baseline for serum HCV RNA (in the log10 scale) through day 22 (defined as DAVG22).
Primary • Median rate of decline in serum HCV RNA (log10 IU/mL/day) through day 22.
Primary • Median rate of change in serum HCV RNA (log10 IU/mL/day) from day 22 (after the last administration) through day 50 (rebound).
Primary • Median change from day 22 (after the last administration) in serum HCV RNA (log10 IU/mL) at day 50 (rebound).
Primary • Descriptive analysis of changes in the HCV genome (NS5B region coding for RNA dependent RNA polymerase) that may be associated with two weeks of
Primary XTL 2125 monotherapy.
See also
  Status Clinical Trial Phase
Completed NCT01708889 - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction Phase 1
Active, not recruiting NCT00563173 - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients Phase 1/Phase 2
Withdrawn NCT01813266 - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed NCT01121731 - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Phase 1/Phase 2
Completed NCT00851890 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT04387539 - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants Phase 1/Phase 2
Completed NCT04391985 - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients Phase 1/Phase 2
Completed NCT00770198 - sgp130 in Chronic Human Liver Disease N/A
Completed NCT04382937 - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection Phase 3
Completed NCT00606528 - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy N/A
Recruiting NCT00294489 - Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT Phase 3
Completed NCT00570336 - Study of CTS-1027 in Hepatitis C Patients Phase 2
Completed NCT02292719 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection Phase 2
Terminated NCT01080222 - A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Phase 2
Completed NCT04385407 - Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Phase 2
Completed NCT04387526 - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 Phase 2/Phase 3
Completed NCT00215865 - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy Phase 3